The ongoing pursuit of migraine triggering mechanisms

Although novel treatments have emerged, migraine continues to impose a substantial global health burden, with ongoing research providing deeper insights into its underlying pathophysiological mechanisms. Provocation studies in migraine patients have offered significant insights into the underlying mechanisms of migraine. The role of ATP-sensitive potassium (K_ATP) channels has gained increasing attention, following studies demonstrating that intravenous (IV) infusion of levcromakalim, a K_ATP channel opener, induces migraine attacks in 82–100% of migraine patients with time of onset ranging between minutes to 12 hours post-infusion (1). Provocation studies with nitroglycerine, calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) induce migraine attacks with lower incidence in comparison to levcromakalim (2,3).

Mechanistically, levcromakalim belongs to a class of drugs used to treat hypertension by promoting smooth muscle relaxation through the activation of potassium channels (4). The rapid and consistent induction of migraine attacks by levcromakalim has considered it as one of the most potent models for studying migraine mechanisms. Importantly, it sparked new discussions around the importance of the blood vessels and vasodilation in migraine pathophysiology, after the demonstration that infusion of a selective neuronal K_ATP channel opener, for the Kir6.2/SUR1 channel subtype, does not induce migraine attacks (5).

This recent randomized, double-blind, placebo-controlled, two-way crossover study by Zhuang et al. (6) investigated whether early IV administration of sumatriptan prevents the onset of levcromakalim-induced migraine attacks, in adults diagnosed with migraine without aura. The study reports that migraine incidence was 75% following sumatriptan administration and 85% following placebo, with no statistically significant difference and a median time of migraine onset of 180 minutes in both groups. This is an important result in the quest to understand migraine pathophysiology.

Opening of vascular K_ATP channels, rather than neuronal K_ATP channels, can trigger migraine attacks. However, despite inducing significant vasoconstriction, intravenous sumatriptan cannot block migraine-like attacks caused by the opening of vascular K_ATP channels, as demonstrated in this study. Indeed, although IV sumatriptan intervention fully reversed superficial temporal artery dilation caused by levcromakalim, it did not prevent the subsequent migraine attack. This dissociation, between vasoconstriction and pain resolution, suggests that intracranial vasodilation may not be the sole trigger in migraine pathogenesis.

Therefore, the mechanism by which levocromakalin induces migraine attacks involves the downstream activation of molecular pathways and the release of inflammatory mediators that can either activate the trigeminal system or influence migraine pathophysiology, independent of, at least, vascular 5HT1_B/D activation. Which molecular pathways may contribute remains to be investigated. Opening of K_ATP channels in the vasculature triggers a series of molecular events, including smooth muscle hyperpolarization, reduced calcium influx and activation of signalling pathways such as endothelial nitirc oxide synthase, protein kinase C and mitogen-activated protein kinase, leading to vasodilation (7,8). These effects occur independently of 5HT1_B/D receptor activation, highlighting distinct mechanisms in migraine pathophysiology.

Interestingly, based on evidence from other migraine triggers that induce vasodilation (e.g., PACAP, vasoactive intestinal peptide, CGRP), Zhuang et al. (6) suggest that intracranial vasodilation may serve as an indicator of the extent to which molecular triggers activate potassium channels. This activation leads to an increase in extracellular potassium at the neurovascular interface, which may play a role in activating and sensitizing perivascular nociceptors.

Despite its strengths, the study has certain limitations. The study population did not include previously identified sumatriptan responders because only nine out of 20 participants were triptan users. Zhuang et al. (6) based their assumption on IV sumatriptan response from outcomes reported in small studies. Sumatriptan given as an intravenous bolus of 64 μg/kg has been shown to offer headache relief in >90% of cases, and pain freedom in about 50% of patients within 20 minutes, potentially due to the rapid pharmacodynamic effects (9,10). The small sample size (n = 20 completing participants) may have limited the statistical power to detect subtle effects or allow for interindividual variability in treatment response.

Of interest, a post-hoc analysis designed by the study team following failure of meeting the primary end-point, showed that sumatriptan significantly reduced the headache intensity. This confirms sumatriptans benefit in headache mitigation/modulation rather than prevention, providing a clinically relevant outcome measure.

Nevertheless, these findings underscore the multifaceted nature of migraine and put the focus of migraine pathophysiology back to the neurovascular interface. Such advancing research is much needed in elucidating migraine's underlying mechanisms and the need for novel therapeutic approaches.